Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 26-29 November 2012
Four new safety referrals evaluated as impact of new legislation kicks in
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) held its fifth meeting from 26-29 November 2012.
At the meeting, the PRAC started a review of four medicines that are nationally authorised in EU Member States. The Committee also evaluated evidence for new safety signals from EU reporting systems, assessed updated risk management plans for certain medicines and discussed a number of periodic safety update reports.
Since the PRAC’s first meeting in July 2012, fresh procedures have started under the new pharmacovigilance legislation. The increasing number of reviews for the PRAC, triggered by EU Member States, indicates that the legislation is working effectively and underlines that Member States view the PRAC as the effective mechanism for assessing all aspects of risk management for human medicines.
For an overview of all information available following the meeting of the PRAC, see the table below:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/11/news_detail_001666.jsp&mid=WC0b01ac058004d5c1
The minutes from the fourth PRAC meeting, which took place from 29-31 October 2012, will be published early next week.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
